论文信息 - Novel OK-432-conjugated Tumor Vaccines Induce Tumor-specific Immunity against Murine Tongue Cancer

Novel OK-432-conjugated Tumor Vaccines Induce Tumor-specific Immunity against Murine Tongue Cancer

Priming with tumor antigens is one of the most important strategies in cancer immunotherapy. To enhance tumor antigenicity, OK-432, a streptococcal preparation, was coupled to squamous cell carcinoma (KLN-205) by means of a 0.2% glutaraldehyde method. The purpose of this study was to investigate whether OK-432-conjugated tumor vaccines could induce tumor-specific immunity. Our originally developed mouse tongue cancer model was used throughout this work for the analysis of antitumor effects. Prepared OK-432-conjugated KLN-205 vaccines were immunized 3 times to DBA/2 mice. The results showed that the KLN-205 vaccines induced cytolytic activity and strongly suppressed both KLN-205 tumor incidence and growth, and survival of the mice was improved. Moreover, the histological results showed that a greater number of lymphocytes had infiltrated around tumor cells by 24 hours after tumor inoculation in the vaccine group. These results suggest that immunizations with KLN-205 vaccines increase the antitumor effects against tongue cancer.

[1] H. Yamana,et al. A Gene Encoding Antigenic Peptides of Human Squamous Cell Carcinoma Recognized by Cytotoxic T Lymphocytes , 1998, The Journal of experimental medicine.

[2] Dirk Schadendorf,et al. Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[3] H. Kiyono,et al. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate , 1995, Nature Medicine.

[4] N. Ishida,et al. Adoptive immunotherapy by pantropic killer cells recovered from OK-432-injected tumor sites in mice. , 1988, Cancer research.

[5] H. Bukawa,et al. Antibody Responses Raised against a Conformational V3 Loop Peptide of HIV‐1 , 1995, Microbiology and immunology.

[6] M. Hanna,et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial , 1999, The Lancet.

[7] S. Rosenberg,et al. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.

[8] M. Minami,et al. Experimental anticancer studies. XXXI. On the streptococcal preparation having potent anticancer activity. , 1966, The Japanese journal of experimental medicine.

[9] M. Kondo,et al. Efficacy of in vitro sensitized cells generated by in vivo priming with OK-432 for adoptive immunotherapy of the poorly immunogenic B16-Bl6 melanoma. , 1996, International journal of immunopharmacology.